Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma
In conclusion, we demonstrate that on-site adaptive manufactured LV20.19 CAR T cells are feasible, safe, and efficacious for R/R MCL with best ORR of 100%, a favorable safety profile, and few relapses to date.
Authors
- Anthony E. Zamora (ORCID: https://orcid.org/0000-0001-5712-5339)
- Mehdi Hamadani (ORCID: https://orcid.org/0000-0001-5372-510X)
- Mauricio Vargas‐Cortes
- Ashley M. Cunningham (ORCID: https://orcid.org/0000-0003-2104-0119)
- Daniel Bucklan
- Anikó Szabó (ORCID: https://orcid.org/0000-0002-8129-0614)
- Parameswaran Hari (ORCID: https://orcid.org/0000-0002-8800-297X)
- Peiman Hematti (ORCID: https://orcid.org/0000-0001-5836-4497)
- Tyce Kearl
- Alfredo Colina (ORCID: https://orcid.org/0000-0002-3675-3608)
- Fateeha Furqan (ORCID: https://orcid.org/0000-0001-7262-4953)
- Timothy S. Fenske (ORCID: https://orcid.org/0000-0001-7069-0025)
- Bryon D. Johnson (ORCID: https://orcid.org/0000-0001-7416-3396)
- Katie Palen
- Michael B. Dwinell (ORCID: https://orcid.org/0000-0001-5372-633X)
- Dina Schneider (ORCID: https://orcid.org/0000-0001-7130-7374)
- Nirav Niranjan Shah (ORCID: https://orcid.org/0000-0002-4336-1071)
- Walter Longo
- Jessica L. Schmeling
Institutions
- Medical College of Wisconsin (US)
- Lentigen Technology (United States) (US)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2025-03-31
- DOI
- https://doi.org/10.1200/jco-24-02158
- Citations
- 8
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 8.36